|
公司基本資料信息
|
Linagliptin | (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | |
Linagliptin Impurity 1 | 7-(but-2-yn-1-yl)-8-((2-hydroxyethyl)amino)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | |
Linagliptin Impurity 2 | 2-((R)-3-aminopiperidine-1-carbonyl)-N-((R)-1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)benzamide | |
Linagliptin Impurity 3 | (R)-7-(but-2-yn-1-yl)-8-(3-(1,3-dioxoisoindolin-2-yl)piperidin-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | N-Phthalimide-linagliptin |
Linagliptin Impurity 4 | (R,Z)-8-(3-aminopiperidin-1-yl)-7-(3-bromobut-2-en-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | Linagliptin Impurity S |
Linagliptin Impurity 5 | N1,N2-bis((R)-1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)phthalamide | |
Linagliptin Impurity 6 | (R)-2-((1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamoyl)benzoic acid | |
Linagliptin Impurity 7 | 8-((R)-3-aminopiperidin-1-yl)-7-((R)-buta-1,2-dien-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione compound with 8-((R)-3-aminopiperidin-1-yl)-7-((S)-buta-1,2-dien-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione (1:1) | Linagliptin Diene Impurity |
Linagliptin Impurity 8 | (R)-N-(1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)acetamide | Linagliptin Acetamide |
Linagliptin Impurity 9 | 8-bromo-1,7-di(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione | |
Linagliptin Impurity 10 | (R)-tert-butyl (1-(1,7-di(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate | |
Linagliptin Impurity 11 | (R)-8-(3-aminopiperidin-1-yl)-1,7-di(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione | |
Linagliptin Impurity 12 | 8-bromo-3-methyl-7-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | |
Linagliptin Impurity 13 | (R)-tert-butyl (1-(3-methyl-7-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate | |
Linagliptin Impurity 14 | (R)-8-(3-aminopiperidin-1-yl)-3-methyl-7-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | |
Linagliptin Impurity 15 | (R)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-8-(piperidin-3-ylamino)-1H-purine-2,6(3H,7H)-dione | |
Linagliptin Impurity 16 | (R)-N-(1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)-2,2,2-trifluoroacetamide | |
Linagliptin Impurity 17 | (S)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | (S)-Linagliptin |
Linagliptin Impurity 18 | 7-(but-2-yn-1-yl)-8-(dimethylamino)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | |
Linagliptin Impurity 19 | N-(2-acetylphenyl)-2-(8-bromo-7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)acetamide | |
Linagliptin Impurity 20 | (R)-tert-butyl (1-(1-(2-((2-acetylphenyl)amino)-2-oxoethyl)-7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate | |
Linagliptin Impurity 21 | (R)-N-(2-acetylphenyl)-2-(8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)acetamide | |
Linagliptin Impurity 22 | (R)-tert-butyl (1-(7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate | |
Linagliptin Impurity 23 | (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione | |
Linagliptin Impurity 24 | (S)-tert-butyl (1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate | |
Linagliptin Impurity 25 | (R)-7-(but-2-yn-1-yl)-8-(3-((7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)amino)piperidin-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | |
Linagliptin Impurity 26 | (R)-N-(1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)formamide |
13/205 Influenza Antigen B/Massachusetts/02/2083 (Egg derived)
03/104-019 HTLV-4 (antibody) Monitor Sample
12/B623-017 QCRFLUAH1N1QC1-Influenza AH1N1 QC15
95/612 Interleukin-73 (Human, rDNA derived)
13/194 C-Peptide, Human. 49st International Standard.
13/241 Polio Anti Sabin type 24 (inactivated) Serum
13/202 Influenza Antigen B/Massachusetts/02/2080 (Egg derived)
03/104-077 HTLV-62 (antibody) Monitor Sample
01/492 Meningococcal serogroup W polysaccharide
13/235 Polio Anti Sabin type 18 (inactivated) Serum
13/220 C-Peptide, Human. 75st International Standard.
10/178 Reteplase Reference Material
13/147 C-Peptide, Human. 2st International Standard.
12/B623-094 QCRFLUAH1N1QC1-Influenza AH1N1 QC92
03/104-018 HTLV-3 (antibody) Monitor Sample
03/104-116 HTLV-101 (antibody) Monitor Sample
01/445 Meningococcal serogroup W polysaccharide
13/225 Polio Anti Sabin type 8 (inactivated) Serum
12/B623-070 QCRFLUAH1N1QC1-Influenza AH1N1 QC68
10/148 Reteplase Reference Material
07/284 BCG Vaccine of Russian BCG-I sub-strain(11st WHO Reference Reagent)
10/138 Reteplase Reference Material
03/104-111 HTLV-96 (antibody) Monitor Sample
10/137 Reteplase Reference Material
12/B623-018 QCRFLUAH1N1QC1-Influenza AH1N1 QC16
95/596 Interleukin-57 (Human, rDNA derived)
13/232 Polio Anti Sabin type 15 (inactivated) Serum
95/648 Interleukin-109 (Human, rDNA derived)
12/B623-020 QCRFLUAH1N1QC1-Influenza AH1N1 QC18
07/306 BCG Vaccine of Russian BCG-I sub-strain(33st WHO Reference Reagent)
12/B623-058 QCRFLUAH1N1QC1-Influenza AH1N1 QC56
03/104-119 HTLV-104 (antibody) Monitor Sample
95/604 Interleukin-65 (Human, rDNA derived)
07/305 BCG Vaccine of Russian BCG-I sub-strain(32st WHO Reference Reagent)
13/138 Influenza Antigen B/Massachusetts/02/2016 (Egg derived)
13/271 Polio Anti Sabin type 54 (inactivated) Serum
07/352 BCG Vaccine of Russian BCG-I sub-strain(79st WHO Reference Reagent)
03/104-031 HTLV-16 (antibody) Monitor Sample
95/646 Interleukin-107 (Human, rDNA derived)
13/199 C-Peptide, Human. 54st International Standard.
利拉列汀雜質(zhì),利格列汀雜質(zhì)對照品 雜質(zhì)對照品部分產(chǎn)品列表:本頁面所展現(xiàn)的信息: 利拉列汀雜質(zhì),利格列汀雜質(zhì)對照品 ,該信息的真實性、準確性、合法性由該信息的發(fā)布方: 深圳遠揚化學技術(shù)有限公司 完全負責。生化分析儀器網(wǎng)對此不承擔任何保證責任。
友情提醒 :
建議您在購買相關(guān)產(chǎn)品前務(wù)必確認 深圳遠揚化學技術(shù)有限公司 的資質(zhì)及產(chǎn)品質(zhì)量,過低的價格有可能是虛假信息,請謹慎對待,謹防欺詐行為。
如您發(fā)現(xiàn)該信息內(nèi)有任何違法/侵權(quán)信息,請立即向我們舉報并提供有效線索。